Ipsen Acquires Epizyme to Broaden its Oncology Portfolio
By Ayush Saxena
Pharma Deals Review: Vol 2022 Issue 7 (Table of Contents)
Published: 14 Jul-2022
DOI: 10.3833/pdr.v2022.i7.2704 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a bid to expand its oncology franchise, Ipsen has agreed to acquire Epizyme, a commercial-stage biopharmaceutical company focused on developing epigenetic medicines for the treatment of cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS